NT-0150 / NodThera - LARVOL DELTA

NT-0150-P001: A study investigating the safety, absorption, and elimination of NT 0150, a new compound that may potentially be used in the treatment of brain disorders, like Alzheimers disease and Parkinsons disease. (clinicaltrialsregister.eu) - P1 | N=53 | Recruiting | Sponsor: Nodthera Limited

New P1 trial • Alzheimer's Disease • CNS Disorders • Inflammation • Movement Disorders • Parkinson's Disease

In vivo preclinical efficacy of NT-0150, a brain penetrant small molecule NLRP3 inflammasome inhibitor (Neuroscience 2025) - "Furthermore, intravenously administered NT-0150 reduced the release of IL-1beta in mouse brain interstitial fluid following brain inflammatory challenge (LPS-BzATP) in a novel cerebral open flow microperfusion model.Collectively, our data demonstrate that NT-0150 is highly brain penetrant following oral dosing and exerts potent anti-inflammatory effects across diverse neuroinflammation models. These findings support the therapeutic potential of NT-0150 for targeting NLRP3-dependent neuroinflammatory mechanisms in chronic neurodegenerative diseases and warrant further clinical investigation."

Preclinical • Alzheimer's Disease • CNS Disorders • Movement Disorders • Parkinson's Disease • GFAP • IL1B • IL6 • NLRP3